Veradermics IPO expected to price at top of $14-$16 range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
February 5, 2026 12:35 PM ESTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $1,281.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "LLY already has a broad footprint in the obesity landscape - With what we believe to be the best drug incretin currently and an increasing uptake trend as indicated by scripts + strong data from Retatrutide + additional life cycle management strategies from LLY. We expect LLY to remain the market leader in the obesity space. We model WW peak Lilly revenues from obesity of 78B vs. $43B cons in year 2036E (our model terminal... More
